Share This Author
Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
- A. Hill, S. Khoo, J. Fortunak, Bryony Simmons, N. Ford
- Medicine, EconomicsClinical infectious diseases : an official…
- 6 January 2014
Large-scale manufacture of treatment to cure hepatitis C virus (HCV) is feasible, with target prices of US$100–$250 per 12-week treatment course. These low prices could make widespread access to HCV…
Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus
Minimum costs of treatment and diagnostics to cure hepatitis C virus infection were estimated at US$171‐360 per person without genotyping or US$261‐450 per person with genotypes, assuming that existing large‐scale treatment programs can be established.
Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries
Active Pharmaceutical Ingredients for Antiretroviral Treatment in Low- and Middle-Income Countries: A Survey
- J. Fortunak, R. de Souza, A. Kulkarni, Christopher L King, T. Ellison, Leandro S. M. Miranda
- MedicineAntiviral therapy
- 1 April 2014
The introduction of new fixed-dose combinations for ART and use of new drug delivery technologies could plausibly provide robust, durable ART for all patients in need, at an overall cost that is only moderately higher than what is presently being spent.
Near-Infrared Investigations of Novel Anti-HIV Tenofovir Liposomes
NIR spectral imaging was capable of clearly distinguishing the different batches, both qualitatively and quantitatively, and a linear relationship was obtained correlating the actual drug entrapped and the predicted values obtained from the partial least squares images.
Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment
Generic TKIs could allow significant savings and scaling-up of treatment globally, for over 1 million eligible patients, according to current high prices.
Process Improvements for the Manufacture of Tenofovir Disoproxil Fumarate at Commercial Scale
The three-step manufacturing process used in the synthesis of tenofovir disoproxil fumarate (1) was studied and optimized, leading to a more productive and robust process. The yield was improved from…
Minimum costs to manufacture new treatments for COVID-19
Isolation, characterization and formulation properties of a new plant gum obtained from Cissus refescence
The results obtained in this study establish the fundamental characteristics of CRG, a gum obtained from the stem of Cissus refescence that was pH sensitive and can potentially be used for intestinal drug delivery.
Estimated generic prices for novel treatments for drug-resistant tuberculosis
Competitive large-scale generic manufacture could allow supplies of treatment for 5-10 times more MDR-TB cases within current procurement budgets.